Eurobio Scientific: EB Development Raises Squeeze-Out Offer to €26.55 per Share
EB Development announced its decision to increase the price offered to Eurobio Scientific shareholders from €25.30 to €26.55 per share, representing a premium of +30.15% according to the initiator.
Public Squeeze-Out Offer Filed with the AMF on September 24, 2026
The transaction in question is a public squeeze-out offer followed by a mandatory withdrawal covering Eurobio Scientific shares. This offer was filed with the Financial Markets Authority (AMF) on September 24, 2026 by EB Development.
The announced revision concerns the price offered for the shares. Eurobio Scientific, whose head office is located in Ulis (Essonne), operates in in vitro diagnostics and medical biology reagents.
Premiums Ranging from +18.68% to +32.61% on Volume-Weighted Average Prices
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to EB Development, the new price reflects premiums of +32.61% compared to the volume-weighted average price over 20 days and +28.77% over 60 days.
These premiums stand at +21.78% over 120 days and +18.68% over 180 days, always compared to volume-weighted average prices.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 84,5 millions d'euros
Quarterly revenue: 84,5 millions d'euros
Net income: 4,7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
